Glenmark Launches Winlevi In Europe; Shares Edge Higher

Mumbai, June 11: Glenmark Pharmaceuticals announced the launch of Winlevi (clascoterone 10 mg/g cream) across key European markets for the treatment of acne vulgaris in adults and adolescents.

The launch was undertaken through Glenmark Specialty S.A. (GSSA), the company’s wholly-owned subsidiary, following marketing authorization granted by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals, in October 2025.

According to the company’s exchange disclosure, Glenmark has initiated direct commercialization in several European regions including the Nordics, Central Europe and Spain. In Portugal, the product will be marketed through a strategic partner arrangement.

The company also said it is pursuing additional launches through commercial partnerships in other European markets as part of its broader dermatology expansion strategy.

Winlevi is described as the first topical acne therapy in over four decades with a novel mechanism of action. The active ingredient, clascoterone, works as a topical androgen receptor inhibitor targeting sebum production and inflammation without systemic anti-androgen effects.

Glenmark noted that acne vulgaris remains one of the most common dermatological conditions globally, with significant prevalence among adolescents and young adults.

Stock Market Snapshot

Glenmark Pharmaceuticals share price traded in positive territory after the company announced the European rollout of its dermatology product.

The stock was trading at ₹2,151.80, up 0.35%, as of 11:53 IST on June 11, 2026, according to exchange data.

Glenmark Pharmaceuticals share price saw modest gains as investors assessed the company’s continued push into specialty dermatology therapies and expansion across regulated international markets.

Market participants also tracked the launch as a step toward strengthening Glenmark’s branded formulations business in Europe through differentiated therapies and targeted partnerships.

Product Launch Marks Strategic Milestone for Glenmark

The company stated that the launch marks Glenmark’s first New Chemical Entity (NCE) launch in Europe and reflects its strategy of building a differentiated dermatology portfolio globally.

Senior management indicated that the rollout strengthens the company’s commercial footprint in Europe while reinforcing execution capabilities across direct launches and strategic collaborations.

Executives from Cosmo Pharmaceuticals also highlighted the launch as an important milestone in the long-standing partnership between the two companies.

Industry analysts note that specialty dermatology remains a high-value segment within global pharmaceuticals, particularly for differentiated topical therapies with limited direct competition.

Company Background

Glenmark Pharmaceuticals is a research-driven pharmaceutical company with operations spanning branded formulations, generics and specialty therapies across multiple global markets.

The company has a presence in more than 80 countries and maintains a portfolio focused on respiratory, dermatology and oncology therapies.

Cosmo Pharmaceuticals is a Europe-based healthcare company focused on dermatology, MedTech AI, gastrointestinal therapies and contract manufacturing services.

Conclusion

The European launch of Winlevi strengthens Glenmark’s positioning in specialty dermatology and marks a significant step in its international branded business strategy.

While the immediate market reaction remained measured, the launch reinforces Glenmark’s broader focus on differentiated therapies and expansion across regulated global pharmaceutical markets.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_11062026102023_BSE_NSE_PressRelease_signed.pdf